Jiangsu Atom Bioscience and Pharmaceutical Co. Ltd. has received FDA clearance of its IND application for a phase I trial in the U.S. of ABP-745, an anti-inflammatory oral small-molecule drug, for the treatment of acute gout.
Aurinia Pharmaceuticals Inc. has submitted an IND application to the FDA for AUR-200, a potential next-generation therapy for B-cell-mediated autoimmune diseases.
Dice Alpha Inc. has disclosed IL-17A inhibitors reported to be useful for the treatment of psoriasis, radiographic axial spondyloarthritis (ankylosing spondylitis), hidradenitis suppurativa, spondyloarthritis, psoriatic and rheumatoid arthritis.
Rheumatoid arthritis (RA) is a systemic autoimmune disorder where Bruton tyrosine kinase (BTK) and Janus kinase 3 (JAK3) are among the most relevant signaling pathways involved.
Shanghai Meiyue Biotech Development Co. Ltd. has identified MAPK p38 inhibitors reported to be useful for the treatment of cancer, arthritis, psoriasis, systemic lupus erythematosus, diabetes, atherosclerosis and Alzheimer’s disease.
A multi-institutional research team has suggested that aberrant TDP-43 processing of the pre-mRNA of a microtubule-associated protein, stathmin-2 (STMN2), may be the primary contributor to amyotrophic lateral sclerosis (ALS).
Researchers from Seoul National University presented results of preclinical evaluation of a new TNF-α/OX40L bispecific antibody, IMB-101, being developed for the treatment of rheumatoid arthritis (RA).
Anaptysbio Inc. has signed an exclusive license agreement for Centessa Pharmaceuticals plc’s blood dendritic cell antigen 2 (BDCA-2) modulator antibody portfolio, including lead asset CBS-004 (to be renamed ANB-101) and related family of backup antibodies, for the treatment of autoimmune and inflammatory diseases.
Treatment of osteoarthritis (OA) is still a challenge, since it is focused on symptom relief but fails at dealing with the progressive cartilage deterioration that occurs during the disease. Researchers from Innovo Therapeutics Inc. recently unveiled INV-1498, a caspase inhibitor, as a preclinical candidate for the treatment of OA.
Inhibition of receptor-interacting serine/threonine-protein kinase 2 (RIPK2) has been previously described as a promising strategy for the treatment of inflammatory bowel disease, as RIPK2 is a key player in the signaling leading to bacterial peptidoglycan (PGN)-induced inflammation and it amplifies pro-inflammatory responses in the intestine.
RSS
